Lavipharm S.A. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported sales was EUR 39.72 million compared to EUR 37.64 million a year ago. Net income was EUR 1.72 million compared to EUR 2.09 million a year ago.

Basic earnings per share from continuing operations was EUR 0.1011 compared to EUR 0.1269 a year ago. Diluted earnings per share from continuing operations was EUR 0.1011 compared to EUR 0.1269 a year ago.